Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accumulated Expenses (2022 - 2026)

Immunome filings provide 5 years of Accumulated Expenses readings, the most recent being $21.9 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 630.97% to $21.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.9 million, a 630.97% increase, with the full-year FY2025 number at $41.7 million, up 25.54% from a year prior.
  • Accumulated Expenses hit $21.9 million in Q1 2026 for Immunome, down from $41.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $41.7 million in Q4 2025 to a low of $1.0 million in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $5.0 million (2022), compared with a mean of $12.3 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 68.78% in 2024 and later soared 674.25% in 2025.
  • Immunome's Accumulated Expenses stood at $4.9 million in 2022, then surged by 62.75% to $8.0 million in 2023, then soared by 313.42% to $33.2 million in 2024, then grew by 25.54% to $41.7 million in 2025, then tumbled by 47.47% to $21.9 million in 2026.
  • The last three reported values for Accumulated Expenses were $21.9 million (Q1 2026), $41.7 million (Q4 2025), and $25.3 million (Q3 2025) per Business Quant data.